Briya Expands Real-World Data Network and Aligns Platform With Evolving FDA Evidence Standards

Briya spent the week underscoring its role as a real-world data and healthtech infrastructure provider, highlighting a rapidly expanding network and growing regulatory relevance. At the HLTH Europe conference, the company showcased access to more than 120 million patient journeys spanning multiple countries, new data sources, and wider therapeutic areas.

Briya is positioning this scale as core research infrastructure, emphasizing AI-ready, globally representative data that can support more complex questions and faster evidence generation. This approach aims to deepen integration into drug development, outcomes research, and real-world evidence workflows for pharma, biotech, and healthtech clients.

In parallel, the company drew attention to shifting U.S. FDA expectations that increasingly accept a single well-controlled trial supplemented by confirmatory real-world evidence. Briya highlighted that the main bottleneck is no longer data access but the ability to process, standardize, and analyze large volumes of structured and unstructured clinical data.

Executives including Co-Founder and CEO David Lazerson, alongside Prof. Fabio Lievano, discussed how integrating disparate data sources into complete patient journeys could help biopharma sponsors meet emerging regulatory standards. This focus suggests Briya is aligning its platform with demand for regulatory-grade real-world evidence, potentially increasing its strategic relevance in clinical development and post-marketing studies.

The company also emphasized thought leadership through the participation of Director of Medical Research Solutions Dr. Or Shaked in the AI4Purpose seminar. His transition from clinical practice to healthtech was framed as emblematic of a wider shift toward scalable, data-driven research foundations.

By associating with specialist forums such as AI4Purpose and major industry events like HLTH Europe, Briya is seeking greater visibility among stakeholders in AI-enabled healthcare and evidence generation. Collectively, the week’s activities reinforce Briya’s positioning at the intersection of clinical expertise, advanced data infrastructure, and evolving regulatory requirements, supporting its long-term partnership and growth prospects.